

06 Feb 2020 | News

QUOTED. 6 February 2020. Andrew Newland.

by

Liquid biopsy firm Angle PLC says it will progress a de novo US FDA submission for its Parsortix blood test by March. The company held a Q-submission meeting with the agency last month to discuss regulatory requirements. See what Angle CEO Andrew Newland said about it here.

“We were happy that all the critical issues that we wanted to address, were addressed, and we got the clear guidance.” – Andrew Newland, CEO, Angle PLC

- Find out more: [Angle Targets March For US FDA De Novo Submission](#)

[Click here](#) for a free trial of *Medtech Insight*